Clinical trials: Focal Onset Seizure
Epilepsy
Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097
This Phase 3 trial is an open-label extension study of the placebo-controlled, double-blind VRX-RET-E22-302 trial. Patients who have completed the VRX-RET-E22-302 trial and who meet inclusion and exclusion criteria will be…
- Trial name
- NCT00310388
- Testing
- Retigabine (INN), Ezogabine (USAN)
- Where
- 67 sites in Australia, Belgium and 10 more
- Volunteers
- 376 people
- Sponsor
- GlaxoSmithKline
Epilepsy, Simple Partial Seizures
Remegal Fixed Dose as Adjunctive Therapy in Patients With Partial Seizures
The purpose of this study is to determine weather Remegal in fixed dosage 1500 mg/daily is effictive and safe in patients with epilepsy with partial seizures
- Conditions
- Epilepsy, Simple Partial Seizures, Complex Partial Seizures, Partial Seizures With Secondary Generalization
- Trial name
- NCT01749046
- Testing
- Remegal
- Where
- 9 sites in Russia
- Volunteers
- 224 people
- Sponsor
- Valexfarm
Epilepsy, Seizures
EpiCare@Home Validation Study for Focal Onset Seizures
The goal of this clinical trial is to validate a wearable seizure monitoring device, EpiCare@Home, as an objective seizure monitoring tool for people with focal onset epileptic seizures.
- Conditions
- Epilepsy, Seizures, Seizures, Focal, Seizure, Refractory
- Trial name
- NCT05738226
- Testing
- EpiCare@Home, wearable multimodal seizure monitoring system
- Where
- United States
- Sponsor
- Byteflies
Neuralgia, Epilepsy
Clinical Study With Lyrica In Patients Suffering From Epilepsy
Clinical study with Lyrica (pregabalin) in patients suffering from epilepsy. This drug is used as adjunctive therapy with one or more antiepileptics. Lyrica has potential to reduce seizure frequency.
- Trial name
- NCT00922987
- Testing
- Lyrica (pregabalin)
- Where
- 61 sites in Slovakia
- Volunteers
- 286 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Partial Seizures (With or Without Secondary Generalized Seizures), Primary Generalized Tonic-clonic Seizures
Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures
The objective of this study is to identify the following in adult epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive…
- Trial name
- FYC01S (NCT03059329)
- Testing
- Fycompa
- Where
- 2 sites in Japan
- Volunteers
- 3,809 people
- Sponsor
- Eisai Co., Ltd.
Epilepsy, Seizures, Epileptic
Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
This study will evaluate the safety and tolerability of SPN-817 in adults with treatment resistant seizures
- Trial name
- NCT05518578
- Testing
- SPN-817
- Where
- 10 sites in United States, Australia
- Volunteers
- 60 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Epilepsy
Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures
This study will evaluate the long term safety and efficacy of pregabalin (Lyrica) when administered by itself (without any other anti-epileptic medication) to epilepsy patients for the treatment of partial seizures.
- Trial name
- NCT00596466
- Testing
- pregabalin
- Where
- 44 sites in United States, Czechia and 2 more
- Volunteers
- 75 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsies, Partial
Effectiveness Study Comparing Treatment With Drug(s) or Adjunctive VNS Therapy for Pharmacoresistant Partial Seizures
To compare outcomes over 12 months of treatment with antiepileptic drugs (AEDs) alone or vagus nerve stimulation (VNS) therapy plus AEDs in patients who have partial seizures refractory to at least two, but not more than five…
- Trial name
- NCT00215215
- Testing
- Vagus Nerve Stimulation Therapy
- Where
- 23 sites in United States
- Volunteers
- 360 people
- Sponsor
- Cyberonics, Inc.
Epilepsy
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
The primary objective of this study is to determine the maximal tolerated dose (MTD) of E2007 given twice daily (bid) or once a day (qd) in patients with refractory partial-onset seizures (including secondarily generalized…
- Trial name
- NCT00144690
- Testing
- E2007 (perampanel)
- Where
- 5 sites in United States
- Sponsor
- Eisai Inc.
Seizures
Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy
This Phase 3 study is being conducted to evaluate the efficacy and safety of retigabine dosed at 1200 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to three…
- Trial name
- RESTORE1 (NCT00232596)
- Testing
- Retigabine
- Where
- 54 sites in United States, Argentina and 3 more
- Volunteers
- 306 people
- Sponsor
- GlaxoSmithKline
Seizures
A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
The goal of this clinical trial is to learn if CVL-865, when taken regularly with other anti-seizure medicines, works to prevent seizures in adults with drug-resistant focal onset seizures.
- Trial name
- NCT04244175
- Testing
- CVL-865
- Where
- 76 sites in United States, Australia and 5 more
- Volunteers
- 154 people
- Sponsor
- AbbVie
Mesial Temporal Lobe Epilepsy
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe…
- Trial name
- EPIC (NCT05135091)
- Testing
- NRTX-1001
- Where
- 36 sites in United States
- Volunteers
- 88 people
- Sponsor
- Neurona Therapeutics
Epilepsy, Partial Seizures
An Open Label Study of Levetiracetam in Japanese Pediatric Patients With Partial Seizures
Objective of the First Period: To evaluate the efficacy of Levetiracetam dry syrup at doses up to a maximum of 60 mg/kg/day or 3000 mg/day used as an adjunctive therapy in Japanese pediatric patients (4 to 16 years) with…
- Trial name
- NCT01063764
- Testing
- Levetiracetam
- Where
- 29 sites in Japan
- Volunteers
- 73 people
- Sponsor
- UCB Japan Co. Ltd.
Partial Seizures
Pregabalin Epilepsy Add-On Trial
To evaluate the efficacy of pregabalin as adjunctive therapy, using a flexible, optimized dose schedule with dose adjustment based on clinical response and tolerability, compared to placebo in subjects with partial seizures
- Trial name
- NCT00141258
- Testing
- pregabalin
- Where
- 5 sites in South Korea
- Volunteers
- 178 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Focal Onset Seizure, Focal Onset Epilepsy
A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
This study will evaluate the safety, pharmacokinetics, and efficacy of three different doses of NBI-921352 versus placebo in adults with focal onset seizures
- Trial name
- NCT05159908
- Testing
- NBI-921352
- Where
- 28 sites in Australia, Belgium and 5 more
- Volunteers
- 101 people
- Sponsor
- Neurocrine Biosciences
Focal Epilepsy
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
- Trial name
- RISE 2 (NCT06132893)
- Testing
- BHV-7000
- Where
- 104 sites in United States, Argentina and 10 more
- Volunteers
- 390 people
- Sponsor
- Biohaven Therapeutics Ltd.
Epilepsy
Pediatric Epilepsy Trial in Subjects 1-24 Months
This study is being conducted to evaluate the effectiveness and safety of LAMICTAL added to the current therapy of pediatric patients age 1-24 months old with partial seizures.
- Trial name
- NCT00043875
- Testing
- lamotrigine
- Where
- 65 sites in United States, Australia and 12 more
- Volunteers
- 177 people
- Sponsor
- GlaxoSmithKline
Epilepsies, Partial
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
Patients with partial seizures currently taking 1-3 antiepileptic medications will have a 50:50 chance to receive Lyrica 300 mg per day or placebo (no active ingredients) added on to their current medications for 3 months.
- Trial name
- NCT00351611
- Testing
- Lyrica (pregabalin)
- Where
- 150 sites in United States, Bulgaria and 7 more
- Volunteers
- 187 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsy
Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy
The purpose of this study is to evaluate the pharmacokinetics (PK) of perampanel during the Maintenance Period of the Core Study following oral suspension administration given as an adjunctive therapy in pediatric participants…
- Trial name
- NCT02914314
- Testing
- perampanel
- Where
- 18 sites in United States, Latvia
- Volunteers
- 26 people
- Sponsor
- Eisai Inc.
Focal Epilepsy With and Without Secondary Generalization
Real-world Clinical Response to Cenobamate Early add-on in France, Germany and Spain
Aim of the study is to better characterize the clinical profile of adjunctive cenobamate by collecting data from the current standard clinical practice in France, Germany, and Spain, to describe the real-world clinical response…
- Trial name
- NCT06716801
- Testing
- Cenobamate
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A